Published in Stroke on May 05, 2005
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol (2010) 9.28
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet (2013) 5.20
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med (2007) 1.54
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology (2010) 1.24
Ischemic stroke in the elderly: an overview of evidence. Nat Rev Neurol (2010) 1.15
Clinical Interaction between Brain and Kidney in Small Vessel Disease. Cardiol Res Pract (2011) 1.10
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther (2012) 1.07
Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med (2009) 1.05
Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics (2009) 1.03
Perinatal nicotine exposure increases vulnerability of hypoxic-ischemic brain injury in neonatal rats: role of angiotensin II receptors. Stroke (2012) 0.98
Fetal stress and programming of hypoxic/ischemic-sensitive phenotype in the neonatal brain: mechanisms and possible interventions. Prog Neurobiol (2012) 0.97
Hypertension in the elderly. World J Cardiol (2012) 0.89
The case for an elderly targeted stroke management. Front Neurol (2011) 0.86
Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion. Br J Pharmacol (2010) 0.86
Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol (2008) 0.86
Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway. Acta Pharmacol Sin (2014) 0.84
Current strategies for ischemic stroke prevention: role of multimodal combination therapies. J Neurol (2007) 0.84
Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther (2010) 0.84
Primary stroke prevention and hypertension treatment: which is the first-line strategy? Neurol Int (2011) 0.84
The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials. PLoS One (2013) 0.83
Stroke prevention: managing modifiable risk factors. Stroke Res Treat (2012) 0.83
Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med (2012) 0.83
Renal denervation prevents stroke and brain injury via attenuation of oxidative stress in hypertensive rats. J Am Heart Assoc (2013) 0.82
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag (2012) 0.81
Lowering of blood pressure for recurrent stroke prevention. Stroke (2014) 0.81
Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol (2008) 0.81
Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br J Pharmacol (2011) 0.80
Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study. Vasc Health Risk Manag (2012) 0.80
Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials. Medicine (Baltimore) (2016) 0.79
Treatment of specific macrovascular beds in patients with diabetes mellitus. Osteopath Med Prim Care (2010) 0.79
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models. PLoS One (2011) 0.79
Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J (2007) 0.79
Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem (2008) 0.79
The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc Health Risk Manag (2009) 0.79
Clinical neuroprotective drugs for treatment and prevention of stroke. Int J Mol Sci (2012) 0.79
Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey. Vasc Health Risk Manag (2014) 0.78
RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract (2013) 0.78
Stroke in chronic kidney disease: prevention and management. Clin J Am Soc Nephrol (2008) 0.78
Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis (2015) 0.78
Antihypertensive drugs and inflammation in acute ischemic stroke as a predictor factor of future cardiovascular mortality. Inflammation (2012) 0.78
Role of blood cell-associated angiotensin II type 1 receptors in the cerebral microvascular response to ischemic stroke during angiotensin-induced hypertension. Exp Transl Stroke Med (2011) 0.78
Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow. J Cereb Blood Flow Metab (2013) 0.77
Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy. Exp Ther Med (2012) 0.77
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection. Vasc Health Risk Manag (2011) 0.77
Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. Stroke (2011) 0.77
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging (2010) 0.77
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Vasc Health Risk Manag (2007) 0.77
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag (2011) 0.76
Secondary prevention of stroke is important: but all hypertensive drugs are not created equal? Stroke (2005) 0.76
Effects of eprosartan on target organ protection. Vasc Health Risk Manag (2006) 0.76
More about the "ARB MI paradox". Heart (2007) 0.76
Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine? Stroke (2006) 0.76
Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. Heart (2005) 0.75
Are racial differences in antihypertensive responsiveness reflected in usage after stroke? J Stroke Cerebrovasc Dis (2007) 0.75
MOSES: superiority or noninferiority? Stroke (2006) 0.75
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. Integr Blood Press Control (2012) 0.75
The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? Am J Cardiovasc Drugs (2016) 0.75
Cardio classics revisited--focus on the role of candesartan. Vasc Health Risk Manag (2010) 0.75
Impact of a better persistence with antihypertensive agents on ischemic stroke outcomes for secondary prevention. PLoS One (2013) 0.75
Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey. Diabetes Metab Syndr Obes (2015) 0.75
Therapeutic potential of the renin angiotensin system in ischaemic stroke. Exp Transl Stroke Med (2016) 0.75
Morbidity and mortality after stroke--eposartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Curr Cardiol Rep (2007) 0.75
A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention. Vasc Health Risk Manag (2009) 0.75
MOSES raises questions. Stroke (2006) 0.75
Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring. J Stroke (2015) 0.75
Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention? Stroke (2006) 0.75
Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis. Medicine (Baltimore) (2017) 0.75
[Therapy of hypertension]. Clin Res Cardiol (2006) 0.75
[Blood pressure goals on the test bench]. Wien Klin Wochenschr (2011) 0.75
Relationship between pre-stroke cardiovascular medication use and stroke severity. Eur J Clin Pharmacol (2015) 0.75
The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients. Intern Emerg Med (2017) 0.75
[Guidelines given by the DSG and DGN concerning stroke therapy--new therapeutic aspects]. Clin Res Cardiol (2006) 0.75
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest (2002) 6.35
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet (2011) 5.17
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke (2003) 4.63
Helicobacter exploits integrin for type IV secretion and kinase activation. Nature (2007) 4.02
Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol (2008) 3.91
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol (2004) 3.18
Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension (2012) 2.95
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 2.36
Control of crystal size and lattice formation by starmaker in otolith biomineralization. Science (2003) 2.35
European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis (2003) 2.35
Effects of multiple deletions of murein hydrolases on viability, septum cleavage, and sensitivity to large toxic molecules in Escherichia coli. J Bacteriol (2002) 2.29
Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation (2004) 2.20
Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension (2013) 2.10
Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer (2008) 2.01
Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells. J Cell Biol (2002) 1.99
Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation (2002) 1.93
Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press Monit (2012) 1.74
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. J Hypertens (2006) 1.74
Chest radiography for the diagnosis of acute aortic syndrome. Am J Med (2004) 1.68
Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) (2007) 1.67
Effect of the venous catheter site on transpulmonary thermodilution measurement variables. Crit Care Med (2007) 1.63
Tissue Doppler imaging identifies myocardial dysfunction in adults with Marfan syndrome. Clin Cardiol (2007) 1.63
Adenosine 5'-tetraphosphate is a highly potent purinergic endothelium-derived vasoconstrictor. Circ Res (2008) 1.61
Differential expression of AT1 receptors in the pituitary and adrenal gland of SHR and WKY. Hypertension (2003) 1.61
Augmentation index relates to progression of aortic disease in adults with Marfan syndrome. Am J Hypertens (2009) 1.60
Specific entry of Helicobacter pylori into cultured gastric epithelial cells via a zipper-like mechanism. Infect Immun (2002) 1.59
Brain nitric oxide synthase activity in spontaneously hypertensive rats during the development of hypertension. J Hypertens (2003) 1.53
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension (2005) 1.52
Predictors of aneurysmal formation after surgical correction of aortic coarctation. J Am Coll Cardiol (2002) 1.51
Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int (2012) 1.50
Prevalences of primary headache symptoms at school-entry: a population-based epidemiological survey of preschool children in Germany. J Headache Pain (2006) 1.47
Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. Biochem Biophys Res Commun (2004) 1.47
Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation (2004) 1.46
Small artery elasticity assessed by pulse wave analysis is no measure of endothelial dysfunction. J Hypertens (2007) 1.46
Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives. J Hypertens (2004) 1.45
Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique. Artif Organs (2013) 1.42
A retrospective comparison of costs for regional and general anesthesia techniques. Anesth Analg (2005) 1.42
The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation (2003) 1.41
Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat. J Hypertens (2002) 1.40
The role of the human cerebellum in short- and long-term habituation of postural responses. Gait Posture (2004) 1.40
Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer (2002) 1.38
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens (2007) 1.36
Remote preconditioning protects the heart by activating myocardial PKCepsilon-isoform. Cardiovasc Res (2002) 1.31
Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res (2004) 1.31
Intramural hematoma of the aorta: predictors of progression to dissection and rupture. Circulation (2003) 1.30
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant (2008) 1.23
Timing of conditioned eyeblink responses is impaired in cerebellar patients. J Neurosci (2005) 1.22
CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol (2002) 1.21
Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med (2005) 1.19
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood (2003) 1.19
Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit (2010) 1.19
Cuticle differentiation during Drosophila embryogenesis. Arthropod Struct Dev (2006) 1.17
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol (2011) 1.17
Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol (2004) 1.17
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. J Hypertens (2004) 1.17
Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med (2004) 1.16
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med (2005) 1.15
Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res (2005) 1.14
A nuclear actin function regulates neuronal motility by serum response factor-dependent gene transcription. J Neurosci (2009) 1.13
Differences in complication rates among the centres in the SPACE study. Neuroradiology (2008) 1.13
High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res (2012) 1.11
Cerebellar involvement in verb generation: an fMRI study. Neurosci Lett (2006) 1.10
Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol (2006) 1.10
Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J (2003) 1.09
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer (2003) 1.08
Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis (2003) 1.08
Noninvasive evaluation of renal allograft fibrosis by transient elastography--a pilot study. Transpl Int (2010) 1.08
The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome. Am J Med Genet A (2008) 1.06
Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun (2007) 1.06
Conserved MIP receptor-ligand pair regulates Platynereis larval settlement. Proc Natl Acad Sci U S A (2013) 1.05
Angiotensin II induces catecholamine release by direct ganglionic excitation. Hypertension (2002) 1.03
Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer. Int J Radiat Oncol Biol Phys (2004) 1.02
Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci (2009) 1.01
Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens (2008) 1.00
Preventing stroke. BMJ (2002) 1.00
Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol (2011) 0.99
Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis (2013) 0.98
Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways. Cardiovasc Res (2007) 0.98
Crenarchaeal biofilm formation under extreme conditions. PLoS One (2010) 0.98
Solvent exposure and malignant lymphoma: a population-based case-control study in Germany. J Occup Med Toxicol (2007) 0.98
Effect of different cost drivers on cost per anesthesia minute in different anesthesia subspecialties. Anesthesiology (2004) 0.97
Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol (2010) 0.97
Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res (2004) 0.97
A physiogenomic approach to study the regulation of blood pressure. Physiol Genomics (2005) 0.97